Mark J. Ratain to Receptor Protein-Tyrosine Kinases
This is a "connection" page, showing publications Mark J. Ratain has written about Receptor Protein-Tyrosine Kinases.
Connection Strength
0.256
-
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58.
Score: 0.233
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.022